PL2453895T3 - (+)-morfinany jako antagonisty receptora toll-like 9 i ich zastosowania terapeutyczne - Google Patents

(+)-morfinany jako antagonisty receptora toll-like 9 i ich zastosowania terapeutyczne

Info

Publication number: PL2453895T3
Authority: PL; Poland
Prior art keywords: morphinans; toll; antagonists; receptor; therapeutic uses
Prior art date: 2009-07-16

Application number

PL10736929T

Other languages

English (en)

Inventor

Bobby N. Trawick

David W. Berberich

Original Assignee

Mallinckrodt Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-07-16

Filing date

2010-07-16

Publication date

2018-10-31

2010-07-16 Application filed by Mallinckrodt Llc filed Critical Mallinckrodt Llc

2018-10-31 Publication of PL2453895T3 publication Critical patent/PL2453895T3/pl

Links

102000008235 Toll-Like Receptor 9 Human genes 0.000 title 1
108010060818 Toll-Like Receptor 9 Proteins 0.000 title 1
239000005557 antagonist Substances 0.000 title 1
INAXVFBXDYWQFN-XHSDSOJGSA-N morphinan Chemical class C1C2=CC=CC=C2[C@]23CCCC[C@H]3[C@@H]1NCC2 INAXVFBXDYWQFN-XHSDSOJGSA-N 0.000 title 1
230000001225 therapeutic effect Effects 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
- C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/18—Aralkyl radicals
- C07D217/20—Aralkyl radicals with oxygen atoms directly attached to the aromatic ring of said aralkyl radical, e.g. papaverine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/22—Bridged ring systems
- C07D221/28—Morphinans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
- C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
- C07D489/08—Oxygen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
- C07D489/09—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems
- C07D489/10—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Oncology (AREA)
Dermatology (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Endocrinology (AREA)
Orthopedic Medicine & Surgery (AREA)
Emergency Medicine (AREA)
Communicable Diseases (AREA)
Hematology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Psychiatry (AREA)
Urology & Nephrology (AREA)
Psychology (AREA)
Cardiology (AREA)
Obesity (AREA)
Ophthalmology & Optometry (AREA)
Otolaryngology (AREA)
Hospice & Palliative Care (AREA)

PL10736929T 2009-07-16 2010-07-16 (+)-morfinany jako antagonisty receptora toll-like 9 i ich zastosowania terapeutyczne PL2453895T3 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US22601509P	2009-07-16	2009-07-16
US28687709P	2009-12-16	2009-12-16
PCT/US2010/042210 WO2011009015A1 (en)	2009-07-16	2010-07-16	(+) - morphinans as antagonists of toll-like receptor 9 and therapeutic uses thereof
EP10736929.0A EP2453895B1 (en)	2009-07-16	2010-07-16	(+) - morphinans as antagonists of toll-like receptor 9 and therapeutic uses thereof

Publications (1)

Publication Number	Publication Date
PL2453895T3 true PL2453895T3 (pl)	2018-10-31

Family

ID=42847568

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL10736929T PL2453895T3 (pl)	2009-07-16	2010-07-16	(+)-morfinany jako antagonisty receptora toll-like 9 i ich zastosowania terapeutyczne

Country Status (11)

Country	Link
US (1)	US20110015219A1 (pl)
EP (1)	EP2453895B1 (pl)
JP (1)	JP5864417B2 (pl)
AU (1)	AU2010273253B2 (pl)
CA (1)	CA2768236C (pl)
DK (1)	DK2453895T3 (pl)
ES (1)	ES2674018T3 (pl)
NO (1)	NO2453895T3 (pl)
PL (1)	PL2453895T3 (pl)
TR (1)	TR201809739T4 (pl)
WO (1)	WO2011009015A1 (pl)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP5688974B2 (ja) *	2007-12-17	2015-03-25	マリンクロッドエルエルシー	（＋）−オピエートの生成のためのプロセスおよび化合物
CA2709862C (en)	2007-12-17	2016-03-15	Peter X. Wang	Sinomenine derivatives and processes for their synthesis
US8829020B2 (en)	2009-07-16	2014-09-09	Mallinckrodt Llc	Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers
US10363251B2 (en)	2009-07-16	2019-07-30	Mallinckrodt Llc	(+)-morphinans as antagonists of toll-like receptor 9 and therapeutic uses thereof
WO2012008984A1 (en) *	2010-07-16	2012-01-19	Mallinckrodt Llc	(+)-morphinans as antagonists of toll-like receptor 9 and therapeutic uses thereof
GB201014026D0 (en) *	2010-08-20	2010-10-06	Ucl Business Plc	Treatment
CN103327977B (zh) *	2011-01-31	2016-05-04	东丽株式会社	恶液质的治疗或预防剂
IN2014DN03009A (pl)	2011-10-26	2015-05-08	Kempharm Inc
CN102617470A (zh) *	2012-03-07	2012-08-01	江苏大学	青藤碱4-羟基醚化和酯化衍生物、制备方法及用途
CN103387539A (zh) *	2012-05-08	2013-11-13	长沙理工大学	4-苄氧基-17-乙酰基吗啡喃-6-酮的合成
CN103387579A (zh) *	2012-05-08	2013-11-13	长沙理工大学	4-苄氧基-17-苯磺酰吗啡喃-6-酮的合成
CA2896202A1 (en)	2012-12-28	2014-07-03	Purdue Pharma L.P.	Substituted morphinans and the use thereof
GB201308440D0 (en) *	2013-05-10	2013-06-19	Dalgleish Angus	Therapeutic
MX371334B (es)	2013-11-18	2020-01-27	SpecGx LLC	Preparacion de normorfinanos.
WO2015082932A1 (en)	2013-12-05	2015-06-11	The University Of Bath	Novel opioid compounds and their uses
WO2016035876A1 (ja) *	2014-09-05	2016-03-10	古河電気工業株式会社	銅箔、銅張積層板、および基板
CA2969221C (en) *	2014-12-02	2021-01-12	Travis Mickle	Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxymorphone, prodrugs, methods of making and use thereof
US10351830B2 (en) *	2014-12-17	2019-07-16	Siemens Healthcare Diagnostics Inc.	Conjugates for assays for oxycodone and oxymorphone
US9757372B2 (en) *	2015-03-25	2017-09-12	Taiwanj Pharmaceuticals Co., Ltd.	Toll-like receptor 4 antagonists and use in autoimmune liver diseases
BR112018011476B1 (pt) *	2015-12-10	2022-04-12	Dsm Ip Assets B.V.	Tabletes comprimidos compreendendo pelo menos uma partícula sólida de vitamina e seu uso
MX2021006804A (es)	2015-12-17	2023-01-13	Merck Patent Gmbh	Antagonistas policiclicos del receptor 7/8 tipo toll (tlr7/8) y uso de los mismos en el tratamiento de trastornos inmunitarios.
US10071079B2 (en)	2016-06-29	2018-09-11	Bristol-Myers Squibb Company	[1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
CN109715617B (zh)	2016-07-30	2022-04-19	百时美施贵宝公司	作为tlr7、tlr8或tlr9抑制剂的二甲氧基苯基取代的吲哚化合物
AU2017311047B2 (en)	2016-08-08	2021-07-22	Merck Patent Gmbh	TLR7/8 antagonists and uses thereof
ES2902504T3 (es)	2016-09-09	2022-03-28	Bristol Myers Squibb Co	Compuestos de indol sustituidos con piridilo
CN110290792A (zh) *	2017-01-05	2019-09-27	景凯生物科技股份有限公司	吗啡喃衍生物和其用于治疗自体免疫、发炎或感染相关的障碍的组合物
US11473145B2 (en)	2017-07-27	2022-10-18	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for determining whether a patient suffering from rhabdomyolysis achieves a response with a TLR9 antagonist
CN107325097B (zh) *	2017-08-04	2019-05-28	北京师范大学	青藤碱衍生物及其制备方法与应用
CN110997670B (zh)	2017-08-04	2022-11-01	百时美施贵宝公司	[1,2,4]三唑并[4,3-a]吡啶基取代的吲哚化合物
CN107337672B (zh) *	2017-08-04	2019-05-28	北京师范大学	一类青藤碱衍生物及其制备方法与应用
EP3661926B1 (en)	2017-08-04	2022-02-23	Bristol-Myers Squibb Company	Substituted indole compounds useful as inhibitors of tlr7/8/9
CN111448190B (zh)	2017-11-14	2023-09-26	百时美施贵宝公司	取代的吲哚化合物
US12030878B2 (en)	2017-12-15	2024-07-09	Bristol-Myers Squibb Company	Substituted indole ether compounds
MX2020006168A (es)	2017-12-18	2020-08-13	Bristol Myers Squibb Co	Compuestos de 4-azaindol.
WO2019126081A1 (en)	2017-12-19	2019-06-27	Bristol-Myers Squibb Company	Amide substituted indole compounds useful as tlr inhibitors
EA202091474A1 (ru)	2017-12-19	2020-11-18	Бристол-Маерс Сквибб Компани	Замещенные индольные соединения, применимые в качестве ингибиторов tlr
EP3728253B1 (en)	2017-12-19	2024-03-27	Bristol-Myers Squibb Company	6-azaindole compounds
KR102730859B1 (ko)	2017-12-20	2024-11-15	브리스톨-마이어스 스큅 컴퍼니	아릴 및 헤테로아릴 치환된 인돌 화합물
JP7287967B2 (ja)	2017-12-20	2023-06-06	ブリストル－マイヤーズスクイブカンパニー	Ｔｌｒ阻害剤として有効なアミノインドール化合物
EA202091530A1 (ru)	2017-12-20	2020-09-14	Бристол-Маерс Сквибб Компани	Диазаиндольные соединения
CA3091826A1 (en)	2018-02-23	2019-08-29	Rhodes Technologies	Novel opioid compounds and uses thereof
ES2963696T3 (es)	2018-10-24	2024-04-01	Bristol Myers Squibb Co	Compuestos diméricos de indol sustituidos
US12172995B2 (en)	2018-10-24	2024-12-24	Bristol-Myers Squibb Company	Substituted indole and indazole compounds
WO2020205735A1 (en) *	2019-03-29	2020-10-08	Humanwell Pharmaceutical US	Novel morphinans useful for treating medical disorders
KR102904576B1 (ko)	2019-05-09	2025-12-24	브리스톨-마이어스 스큅 컴퍼니	치환된 벤즈이미다졸론 화합물
WO2021067326A1 (en)	2019-10-01	2021-04-08	Bristol-Myers Squibb Company	Substituted bicyclic heteroaryl compounds
CN114829350B (zh)	2019-10-04	2024-05-28	百时美施贵宝公司	经取代的咔唑化合物
EP4125990A4 (en) *	2020-03-24	2024-07-03	University of Padova	MORPHINE ISOMERS AND THEIR STRUCTURAL MODIFICATIONS AS NMDAR ANTAGONISTS AND NEUROPLASTIGENS
CN115260098B (zh) *	2022-06-09	2024-06-04	澳门科技大学	Abcb5抑制剂在制备多耐药性类风湿性关节炎治疗药物中的应用
CN121337808A (zh) *	2025-10-17	2026-01-16	暨南大学	一种生物仿生膜包覆载药纳米体系构建方法及应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3438989A (en) *	1967-03-10	1969-04-15	Warner Lambert Pharmaceutical	Process for the production of ( ) dihydrothebainone
US4556712A (en) *	1981-05-20	1985-12-03	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Preparation and racemization of chiral 1-benzyl-1,2,3,4-tetrahydroisoquinolines
US4521601A (en) *	1981-05-20	1985-06-04	The United States Of America As Represented By The Department Of Health & Human Services	Practical total synthesis unnatural enantiomers of opium-derived morphinans
US5668285A (en) *	1986-10-31	1997-09-16	The United States Of America As Represented By The Department Of Health And Human Services	Total synthesis of northebaine, normophine, noroxymorphone enantiomers and derivatives via N-Nor intermediates
PT95069B (pt) *	1989-08-24	1997-10-31	Searle & Co	Processo para a preparacao de (+)-isomeros de derivados de endoetano/endoetanoepoximofinano, uteis como agentes anti-tussicos
NZ268969A (en) *	1993-07-23	1997-06-24	Toray Industries	Morphinan derivatives and pharmaceutical compositions
US5919826A (en) *	1996-10-24	1999-07-06	Algos Pharmaceutical Corporation	Method of alleviating pain
GB2392670A (en) *	2002-09-03	2004-03-10	Stylacats Ltd	(+)-Morphine production
EP2012772A1 (en) *	2006-04-26	2009-01-14	The Uab Research Foundation	Reducing cancer cell invasion using an inhibitor of toll like receptor signaling
CN101066948B (zh) *	2007-05-30	2012-01-04	广东工业大学	青藤碱催化氢化还原制备氢化青藤碱的方法
JP2010533719A (ja) *	2007-07-17	2010-10-28	マリンクロッド・インコーポレイテッド	還元的アミノ化によるｎ−アルキル化オピエートの調製
JP2010536787A (ja) *	2007-08-15	2010-12-02	イデラファーマシューティカルズインコーポレイテッド	Ｔｏｌｌ様受容体モジュレータ
US20110251229A1 (en) *	2007-10-30	2011-10-13	The Regents Of The University Of Colorado	(+)-opioids and methods of use
WO2009078986A1 (en) *	2007-12-17	2009-06-25	Mallinckrodt Inc.	Process for the preparation of buprenorphine and derivatives of buprenorphine
JP5688974B2 (ja) *	2007-12-17	2015-03-25	マリンクロッドエルエルシー	（＋）−オピエートの生成のためのプロセスおよび化合物
CN101265266B (zh) *	2008-04-23	2011-12-14	南京大学	青藤碱衍生物及其制备方法和应用
WO2010028004A2 (en) *	2008-09-03	2010-03-11	Mallinckrodt Inc.	Substituted berbines and processes for their synthesis
CN102227433B (zh) *	2008-09-30	2015-01-07	马林克罗特有限公司	烷基化吗啡喃衍生物的仲胺基团的方法
KR20100090155A (ko) *	2009-02-05	2010-08-13	엘지전자 주식회사	이동 단말기 및 그의 프레즌스 정보 처리방법
US8563724B2 (en) *	2009-02-23	2013-10-22	Mallinckrodt Llc	(+)-6-hydroxy-morphinan or (+)-6-amino-morphinan derivatives
CN102325777B (zh) *	2009-02-23	2015-08-12	马林克罗特公司	(+)-吗啡喃*n-氧化物及其制备方法
CA2764915C (en) *	2009-06-11	2017-07-11	Mallinckrodt Llc	Preparation of 6-alpha-amino n-substituted morphinans by catalytic hydrogen transfer
US8829020B2 (en) *	2009-07-16	2014-09-09	Mallinckrodt Llc	Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers
WO2012008984A1 (en) *	2010-07-16	2012-01-19	Mallinckrodt Llc	(+)-morphinans as antagonists of toll-like receptor 9 and therapeutic uses thereof

2010
- 2010-07-16 PL PL10736929T patent/PL2453895T3/pl unknown
- 2010-07-16 ES ES10736929.0T patent/ES2674018T3/es active Active
- 2010-07-16 DK DK10736929.0T patent/DK2453895T3/en active
- 2010-07-16 TR TR2018/09739T patent/TR201809739T4/tr unknown
- 2010-07-16 US US12/837,545 patent/US20110015219A1/en not_active Abandoned
- 2010-07-16 NO NO10736929A patent/NO2453895T3/no unknown
- 2010-07-16 EP EP10736929.0A patent/EP2453895B1/en active Active
- 2010-07-16 JP JP2012520805A patent/JP5864417B2/ja active Active
- 2010-07-16 CA CA2768236A patent/CA2768236C/en active Active
- 2010-07-16 WO PCT/US2010/042210 patent/WO2011009015A1/en not_active Ceased
- 2010-07-16 AU AU2010273253A patent/AU2010273253B2/en active Active

Also Published As

Publication number	Publication date
AU2010273253A1 (en)	2012-02-09
TR201809739T4 (tr)	2018-07-23
WO2011009015A1 (en)	2011-01-20
DK2453895T3 (en)	2018-08-27
JP5864417B2 (ja)	2016-02-17
NO2453895T3 (pl)	2018-10-20
CA2768236C (en)	2018-05-22
US20110015219A1 (en)	2011-01-20
CA2768236A1 (en)	2011-01-20
ES2674018T3 (es)	2018-06-26
JP2012533561A (ja)	2012-12-27
AU2010273253B2 (en)	2015-03-12
EP2453895B1 (en)	2018-05-23
EP2453895A1 (en)	2012-05-23

Publication	Publication Date	Title
PL2593095T3 (pl)	2019-12-31	(+)-morfinany jako antagoniści receptora toll-podobnego 9 i ich terapeutyczne zastosowania
PT2482812T (pt)	2023-01-24	Composições farmacêuticas compreendendo bi-1356 e metformina
IL218299A0 (en)	2012-04-30	Use of nicotinic acetylcholine receptor alpha 7 acitivators
ZA201200054B (en)	2013-10-30	Therapeutic compounds and compositions
PL2448581T3 (pl)	2017-06-30	Kompozycje terapeutyczne i odnośne sposoby ich stosowania
ZA201207259B (en)	2013-09-25	4-aminopyrimidine derivatives and their as as adenosine 121 receptor antagonists
EP2480225A4 (en)	2013-05-01	DERMAL FORMULATIONS FROM DP2 RECEPTOR ANTAGONISTS
IL225550A0 (en)	2013-06-27	4cxcr receptor antagonists
EP2461809A4 (en)	2013-06-19	OPHTHALMIC PHARMACEUTICAL COMPOSITIONS OF DP2 RECEPTOR ANTAGONSITES
IL218212A0 (en)	2012-04-30	Therapeutic methods and compositions
GB0921075D0 (en)	2010-01-13	Novel combination of the therapeutic agents
IL215690A0 (en)	2012-01-31	Thiazole derivatives and their use as p2y12 receptor antagonists
PL2403505T3 (pl)	2017-06-30	Terapeutyczne zastosowania frakcji gumy mastyksowej
IL215368A0 (en)	2011-12-29	Therapeutic uses of quinazolinedione derivatives
EP2291366A4 (en)	2012-06-06	PREPARATION OF IMATINIB MESYLATE
EP2552447A4 (en)	2013-09-11	STABLE PHARMACEUTICAL COMPOSITION OF IMATINIB
ZA201108724B (en)	2013-06-26	Toll-like receptor 3 antagonists
EP2588143A4 (en)	2014-07-30	NEW AGONISTS OF THE TOLL-LIKE RECEPTOR 3 AND METHODS OF USING THE SAME
GB0900484D0 (en)	2009-02-11	Therapeutic agent
EP2755685A4 (en)	2015-07-01	TOLL-LIKE RECEPTOR-3 ANTAGONISTS FOR THE TREATMENT OF METABOLISM AND CARDIAC DISEASES
EP2461870A4 (en)	2013-04-17	THERAPEUTIC COMPOSITIONS AND METHOD
IL219018A (en)	2016-11-30	Radzolid Pharmaceuticals and Uses
GB0900786D0 (en)	2009-03-04	Therapeutic compositions
HU0900712D0 (en)	2010-01-28	New methods and intermediers for the synthesis of ace-inhibitor
GB0709038D0 (en)	2007-06-20	Novel receptor antagonists and their methods of use